Trial reportDrug and alcohol dependence2010
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.
Trial report in Drug and alcohol dependence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00105482 (Testing the Effectiveness of Low Dose Naltrexone for Smoking Cessation and Minimization of Post-cessation Weight Gain), which is not on this map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testing the Effectiveness of Low Dose Naltrexone for Smoking Cessation and Minimization of Post-cessation Weight Gain
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021Pooled it
- Pooled it
- Opioid antagonists for smoking cessation.The Cochrane database of systematic reviews · 2013Pooled it
- Weight gain in smokers after quitting cigarettes: meta-analysis.BMJ (Clinical research ed.) · 2012Pooled it
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Psychopharmacology · 2014Trial
- Menthol cigarette use predicts treatment outcomes of weight-concerned smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2014Trial
- Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.Addiction (Abingdon, England) · 2013Trial
- Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Biological psychiatry · 2013Trial
- Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.Journal of clinical psychopharmacology · 2012Trial
- A preliminary investigation of varenicline for heavy drinking smokers.Psychopharmacology · 2011Trial
- Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.Journal of addiction medicineTrial
- Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.Psychopharmacology · 2019Article
- Endogenous opioid system: a promising target for future smoking cessation medications.Psychopharmacology · 2017Review
- The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review.Journal of pharmaceutical policy and practice · 2017Review
- Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.Current addiction reports · 2016Article
- The opioid receptors as targets for drug abuse medication.British journal of pharmacology · 2015Review
- Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial.Pharmacogenetics and genomics · 2015Article
- Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.Psychopharmacology · 2014Article
- Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.Addiction biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundFear of weight gain is a significant obstacle to smoking cessation, preventing some smokers from attempting to quit. Several previous studies of naltrexone yielded promising results for minimization of post-quit weight gain. Given these encouraging findings, we endeavored to test whether minimization of weight gain might translate to better quit outcomes for a population that is particularly concerned about gaining weight upon quitting.
methodsSmokers (N=172) in this investigation were prospectively randomized to receive either 25 mg naltrexone or placebo for 27 weeks (1 week pre-, 26 weeks post-quit) for minimization of post-quit weight gain and smoking cessation. All participants received open label therapy with the nicotine patch for the first 8 weeks post-quit and behavioral counseling over the 27-week treatment. The 2 pre-specified primary outcomes were change in weight for continuously abstinent participants and biologically verified end-of-treatment 7-day point-prevalence abstinence at 26 weeks after the quit date.
resultsThe difference in weight at 26 weeks post-quit between the naltrexone and placebo groups (naltrexone: 6.8 lbs ± 8.94 vs placebo: 9.7 lbs ± 9.19, p = 0.45) was not statistically different. Seven-day point-prevalence smoking abstinence rates at 26 weeks post-quit was not significantly different between the 2 groups (naltrexone: 22% vs placebo: 27%, p = 0.43).
conclusionsFor smokers high in weight concern, the relatively small reduction in weight gain with low-dose naltrexone is not worth the potential for somewhat lower rates of smoking abstinence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.